Logo image of CSBR

CHAMPIONS ONCOLOGY INC (CSBR) Stock Fundamental Analysis

NASDAQ:CSBR - Nasdaq - US15870P3073 - Common Stock - Currency: USD

6.43  +0.71 (+12.41%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to CSBR. CSBR was compared to 55 industry peers in the Life Sciences Tools & Services industry. While CSBR is still in line with the averages on profitability rating, there are concerns on its financial health. CSBR is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

CSBR had positive earnings in the past year.
In the past year CSBR has reported a negative cash flow from operations.
In multiple years CSBR reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: CSBR reported negative operating cash flow in multiple years.
CSBR Yearly Net Income VS EBIT VS OCF VS FCFCSBR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of 20.98%, CSBR belongs to the top of the industry, outperforming 96.36% of the companies in the same industry.
CSBR's Return On Equity of 117.52% is amongst the best of the industry. CSBR outperforms 100.00% of its industry peers.
CSBR has a Return On Invested Capital of 49.38%. This is amongst the best in the industry. CSBR outperforms 98.18% of its industry peers.
Industry RankSector Rank
ROA 20.98%
ROE 117.52%
ROIC 49.38%
ROA(3y)-13.95%
ROA(5y)-10.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CSBR Yearly ROA, ROE, ROICCSBR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

CSBR's Profit Margin of 10.97% is amongst the best of the industry. CSBR outperforms 85.45% of its industry peers.
Looking at the Operating Margin, with a value of 11.48%, CSBR is in the better half of the industry, outperforming 67.27% of the companies in the same industry.
With a Gross Margin value of 51.58%, CSBR perfoms like the industry average, outperforming 58.18% of the companies in the same industry.
In the last couple of years the Gross Margin of CSBR has declined.
Industry RankSector Rank
OM 11.48%
PM (TTM) 10.97%
GM 51.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.65%
GM growth 5Y-2.63%
CSBR Yearly Profit, Operating, Gross MarginsCSBR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CSBR is creating value.
The number of shares outstanding for CSBR has been increased compared to 1 year ago.
Compared to 5 years ago, CSBR has more shares outstanding
CSBR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CSBR Yearly Shares OutstandingCSBR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CSBR Yearly Total Debt VS Total AssetsCSBR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of 0.95, we must say that CSBR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CSBR (0.95) is worse than 63.64% of its industry peers.
CSBR has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
CSBR has a Debt to Equity ratio of 0.02. This is in the better half of the industry: CSBR outperforms 67.27% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 0.95
ROIC/WACC4.65
WACC10.63%
CSBR Yearly LT Debt VS Equity VS FCFCSBR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

CSBR has a Current Ratio of 0.99. This is a bad value and indicates that CSBR is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of CSBR (0.99) is worse than 85.45% of its industry peers.
CSBR has a Quick Ratio of 0.99. This is a bad value and indicates that CSBR is not financially healthy enough and could expect problems in meeting its short term obligations.
CSBR has a worse Quick ratio (0.99) than 80.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.99
Quick Ratio 0.99
CSBR Yearly Current Assets VS Current LiabilitesCSBR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

6

3. Growth

3.1 Past

CSBR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 176.81%, which is quite impressive.
Looking at the last year, CSBR shows a quite strong growth in Revenue. The Revenue has grown by 19.03% in the last year.
CSBR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.13% yearly.
EPS 1Y (TTM)176.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%325%
Revenue 1Y (TTM)19.03%
Revenue growth 3Y6.91%
Revenue growth 5Y13.13%
Sales Q2Q%41.77%

3.2 Future

Based on estimates for the next years, CSBR will show a very strong growth in Earnings Per Share. The EPS will grow by 56.78% on average per year.
CSBR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.84% yearly.
EPS Next Y162.45%
EPS Next 2Y56.78%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year15.88%
Revenue Next 2Y11.77%
Revenue Next 3Y17.89%
Revenue Next 5Y17.84%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CSBR Yearly Revenue VS EstimatesCSBR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
CSBR Yearly EPS VS EstimatesCSBR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.2 -0.2 -0.4 -0.6

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 12.13, the valuation of CSBR can be described as correct.
96.36% of the companies in the same industry are more expensive than CSBR, based on the Price/Earnings ratio.
CSBR's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.46.
A Price/Forward Earnings ratio of 28.65 indicates a quite expensive valuation of CSBR.
63.64% of the companies in the same industry are more expensive than CSBR, based on the Price/Forward Earnings ratio.
CSBR's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.30.
Industry RankSector Rank
PE 12.13
Fwd PE 28.65
CSBR Price Earnings VS Forward Price EarningsCSBR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CSBR indicates a rather cheap valuation: CSBR is cheaper than 98.18% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.04
CSBR Per share dataCSBR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

CSBR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CSBR's earnings are expected to grow with 56.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y56.78%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CSBR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHAMPIONS ONCOLOGY INC

NASDAQ:CSBR (6/3/2025, 5:16:00 PM)

6.43

+0.71 (+12.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-12 2025-03-12/bmo
Earnings (Next)07-16 2025-07-16/amc
Inst Owners47.82%
Inst Owner Change3.47%
Ins Owners25.86%
Ins Owner Change0%
Market Cap88.93M
Analysts82.86
Price Target12.24 (90.36%)
Short Float %1.04%
Short Ratio3.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2009.8%
Min EPS beat(2)390.2%
Max EPS beat(2)3629.41%
EPS beat(4)4
Avg EPS beat(4)1146.3%
Min EPS beat(4)106.13%
Max EPS beat(4)3629.41%
EPS beat(8)5
Avg EPS beat(8)540.78%
EPS beat(12)6
Avg EPS beat(12)292.36%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)15.24%
Min Revenue beat(2)1.31%
Max Revenue beat(2)29.17%
Revenue beat(4)4
Avg Revenue beat(4)10.71%
Min Revenue beat(4)1.31%
Max Revenue beat(4)29.17%
Revenue beat(8)4
Avg Revenue beat(8)1.57%
Revenue beat(12)6
Avg Revenue beat(12)0.9%
Revenue beat(16)10
Avg Revenue beat(16)1.14%
PT rev (1m)0%
PT rev (3m)50%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-433.33%
EPS NY rev (1m)0%
EPS NY rev (3m)42.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-23.32%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.8%
Valuation
Industry RankSector Rank
PE 12.13
Fwd PE 28.65
P/S 1.52
P/FCF N/A
P/OCF N/A
P/B 16.26
P/tB 17.32
EV/EBITDA 9.04
EPS(TTM)0.53
EY8.24%
EPS(NY)0.22
Fwd EY3.49%
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS4.24
BVpS0.4
TBVpS0.37
PEG (NY)0.07
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 20.98%
ROE 117.52%
ROCE 62.51%
ROIC 49.38%
ROICexc 70.31%
ROICexgc 73.57%
OM 11.48%
PM (TTM) 10.97%
GM 51.58%
FCFM N/A
ROA(3y)-13.95%
ROA(5y)-10.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.65%
GM growth 5Y-2.63%
F-Score5
Asset Turnover1.91
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA 0.01
Cap/Depr 1.47%
Cap/Sales 0.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.99
Quick Ratio 0.99
Altman-Z 0.95
F-Score5
WACC10.63%
ROIC/WACC4.65
Cap/Depr(3y)106.12%
Cap/Depr(5y)172.76%
Cap/Sales(3y)3.95%
Cap/Sales(5y)5.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)176.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%325%
EPS Next Y162.45%
EPS Next 2Y56.78%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)19.03%
Revenue growth 3Y6.91%
Revenue growth 5Y13.13%
Sales Q2Q%41.77%
Revenue Next Year15.88%
Revenue Next 2Y11.77%
Revenue Next 3Y17.89%
Revenue Next 5Y17.84%
EBIT growth 1Y176.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year162.59%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-146.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-123.77%
OCF growth 3YN/A
OCF growth 5YN/A